The University of Arizona

TCAP - Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia

Summary: 

To assess the efficacy and safety of 90 days of oral ticagrelor in patients hospitalized with severe community acquiresd pneumonia (CAP).  The primary objective is to reduce all-cause mortality in the ticagrelor group compared to the placebo group.

Sponsor: 
Gordon Bernard AstraZeneca